PRECEDENT: A Randomized Phase II Trial Comparing Vintafolide (EC145) and Pegylated Liposomal Doxorubicin (PLD) in Combination Versus PLD Alone in Patients With Platinum-Resistant Ovarian Cancer - Concepedia

Concepedia

Publication | Closed Access

PRECEDENT: A Randomized Phase II Trial Comparing Vintafolide (EC145) and Pegylated Liposomal Doxorubicin (PLD) in Combination Versus PLD Alone in Patients With Platinum-Resistant Ovarian Cancer

227

Citations

17

References

2013

Year

R. Wendel Naumann, Robert L. Coleman, Robert A. Burger, Edward A. Sausville, E. Kutarska, Sharad Ghamande, Nashat Gabrail, Stephen DePasquale, Elżbieta Nowara, Lucy Gilbert,

Journal of Clinical Oncology

Abstract

Vintafolide plus PLD is the first combination to demonstrate an improvement over standard therapy in a randomized trial of patients with platinum-resistant ovarian cancer. Etarfolatide can identify patients likely to benefit from vintafolide.

References

	Year	Citations

Page 1